AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer Published: May 7, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab, Tremelimumab, P-III, POSEIDON Study, Stage IV Non-Small Cell Lung Cancer Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + […]Read More
Shots: Labcorp acquires the Vectra RA test from Myriad Genetics along with other operating assets and IP for $150M in cash. The transaction is expected to close in Q3’21 The divestiture of Myriad auto immune’s Vectra testing business allow Labcorb to bolster its rheumatology and autoimmune portfolios Vectra is a non-invasive, blood-based test that analyzes […]Read More
Shots: Myriad to seek approval based on the P-III PROfound results assessing Lynparza vs enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have failed prior treatment with the hormonal agent with homologous recombination repair gene mutations In 2007, Myriad & AstraZeneca entered into collaboration on Lynparza and has resulted in multiple […]Read More
Shots: AstraZeneca & Merck will utilize Myriads’ BRAC Analysis CDx to identify germline BRCA mutations in men who have mCRPC cancer, enrolled in Phase III PROfound (NCT02987543) study In 2007, Myriad collaborates with AZ for BRAC Analysis CDx to be used as a companion diagnostic to Lynparza (olaparib) and the combination has received approval from […]Read More
Shots: Myriad to provide BRACAnalysis CDx testing device in P-II study conducted to evaluate Pfizer’s talazoparib for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer BRACAnalysis CDx is an IVD device used for qualitative detection and classification of protein coding regions & intron/exon boundaries of BRCA1 and BRCA2 gene In April, 2015 Myriad and […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
